Industry Categories News Contact Us

Japan approves AstraZeneca's lung cancer treatment, Tagrisso

Author : Ojaswita Kutepatil | Published Date : 2018-08-22 

AstraZeneca, a global biopharmaceutical company has reportedly announced the approval of its new lung cancer treatment, Tagrisso by the Japanese Ministry of Health, Labor and Welfare. As per reliable sources, the treatment would be available for the first line treatment of patients suffering from incurable or recurring epidermal growth factor receptor (EGFR).

According to an official press release by AstraZeneca, the approval comes on the heels of the global Phase III FLAURA trial results which were reportedly conducted on numerous Japanese patients. Incidentally, Tagrisso’s safety data in the FLAURA trial is in line with the results observed in prior clinical trials.

As per Dave Fredrickson, Executive VP and Head of AstraZeneca’s Oncology Business Unit, their Tagrisso lung cancer treatment has already been approved by Japan for specifically treating patients with EGFR mutation, which apparently is resistant to the existing 1st-line EGFR-inhibitor medicines.

Fredrickson added that the new approval would promote the use of Tagrisso to the 1st-line setting, eventually replacing older medicines, irrespective of Japan’s high prevalence of EGFR mutation, and would offer a vital treatment alternative.

Reports suggest that the FLAURA trial revealed a superior progression free survival benefit which was consistent across all subgroups including in patients with or without the central nervous system (CNS) metacases, a significant benefit for lung cancer patients.

According to official reports, AstraZeneca's new products progressively provided a boost to the company, helping profits beat the firm’s estimates in the second quarter. Sources also claim that Pascal Soriot, CEO of AstraZeneca was reportedly encountered selling the rights of some medicines in a bid to expedite the company’s revenue and support its new medical research.

Recent reports claim that Tagrisso has received approvals in close to 40 countries for the 1st-line treatment of patients suffering with metastatic EGFRm NSCLC, including the U.S. and Europe.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market research industry. Crafting, reading, and music are some of her other areas of interest.

She can be contacted at- [email protected] | https://twitter.com/ojaswita_k

Related News

Amazon to distribute two VIS produced series in Latin America

Published Date: 2018-11-17         Author: Ojaswita Kutepatil

Amazon and Viacom International Studios have signed a content deal to distribute two VIS produced Latin American series Homens? and Dani Who? to Prime Video. As per credible sources, Homens? is a sitcom starring Fabio Porchat and it revolves around the lives of four close friends. Reliable report... Read More

NextDC invests $2.25 billion to build data centers in Australia

Published Date: 2018-09-02         Author: Ojaswita Kutepatil

Leading data center operator NextDC has declared plans to spend $2.25 billion on sites in Melbourne, Perth, and Sydney. The new sites will be developed into data centers for the likes of drones, nanotechnology and precision medicine. The purchase of the new north shore site has been funded by a r... Read More

Facebook pledges to run data centers on 100% renewable energy by 2020

Published Date: 2018-08-30         Author: Ojaswita Kutepatil

As a part of its pledge to combat climate change, Facebook has recently announced that it will be reducing its greenhouse gas emissions by 75% and will power its global operations with 100% renewable energy by 2020. According to sources familiar with the matter, the social-media behemoth has sign... Read More

© 2018 Fractovia. All Rights Reserved